Halliburton Labs has named its newest cohort — and opened applications for the next one. Photo courtesy of Halliburton

Halliburton Labs has doubled the number of clean energy companies that are operating out of its facilities with the addition of its second cohort.

Four companies have been selected for the program, joining four existing member companies of Halliburton Labs, which originally launched last summer. The companies recently announced to the incubator are Alumina Energy, Ionada, Parasanti, and SurgePower Materials.

"We are excited to support and collaborate with this group of early-stage, clean energy companies as they continue their commercialization journey," says Dale Winger, managing director of Halliburton Labs, in a news release. "Each has demonstrated a commitment to accelerating their technologies, and we are eager to help them innovate, develop and scale each company."

The new companies join existing labs members Nanotech Inc, Enexor BioEnergy, Momentum Technologies, and OCO Inc. Nanotech was the first company to join the labs in August 2020, while the other three were added in February.

With the announcement of the new cohort, Halliburton is now accepting applications for its third cohort. Interested companies can apply via the website, and submissions are due by September 3, 2021.

Alumina Energy

Focusing on providing zero-carbon heat and power solutions, Santa Monica, California-based Alumina Energy has created a patented packed bed thermal energy storage technology that can make renewable energy resources a more reliable and cost competitive source of heat and power.

"We are very excited to join Halliburton Labs' cleantech accelerator program and collaborate with their experienced team to advance cleaner, affordable energy," says Sasha Braun Diamont, founder and CEO of Alumina Energy, in the release.

Ionada

Ionada is based in Ontario, Canada, and also has offices in London and Germany. The company has developed an exhaust gas cleaning systems that's designed to reduce emissions from the marine and power generation industries.

"We are receiving tremendous interest from industrial emitters around the world for modular carbon capture systems. Halliburton Labs' engineering, supply chain expertise and global network provide the ideal launching platform for us to scale our business to meet demand," says Edoardo Panziera, CEO of Ionada, in the release.

Parasanti

Headquartered in Austin, Parasanti is a tech company with software and hardware applications geared toward streaming analytics and production machine learning to enhance data analytics,

"Parasanti could not be more honored to be a part of the Halliburton Labs accelerator. With the domain expertise and wealth of knowledge that Haliburton Labs possesses, this accelerator will position Parasanti to leverage our edge hardware and software technologies to enable new artificial intelligence and machine learning solutions in the energy space," says Parasanti co-founders James Hancock and Joshua Seagroves in the release.

SurgePower Materials

San Marcos-based SurgePower Materials has developed a way to produce high-purity graphene from an abundant renewable raw material — a process that will allow for producing concrete, electronics, renewable energy, and batteries in a more sustainable way.

"Our goal is to make SurgePower Materials the key enabler of the forthcoming graphene age with plant-based graphene as an essential component of many new technologies. Our strategic collaboration with Halliburton Labs allows us to leverage their world-class engineering expertise to rapidly scale our production and accelerate the adoption of new graphene-based solutions," says Dr. Michael Opoku, CEO of SurgePower Materials, in the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”